Covid19 and MortalityNCT04659876
Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
An observational study of Covid19 and Mortality, run by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak. The first cases in this region were seen on March 22, 2020. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid19 and Mortality
- What is being tested?
- clinical features and laboratory values
- How many people
- 445 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 22 Mar 2020to 8 Dec 2020
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Critical patients over the age of 18 who were admitted to the ICU
Who may be able to join
- During the period between 22.03.2020 and 01.09.2020, critical patients over the age of 18 who were admitted to the ICU of Diyarbakır Gazi Yasargil Educational and Research Hospital due to COVID-19 will be included in the study.
Who cannot join
- ICU patients without COVID-19
- COVID-19 patients under 18 years of age
- COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Diyarbakır Gazi Yaşargil Training and Research Hospital
Diyarbakır
About this study
Official title: Clinical Characteristics and Laboratory Values Affecting Mortality in Critical Coronavirus Disease 2019 Patients Followed in the Intensive Care Unit
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak. The first cases in this region were seen on March 22, 2020. In this study, it is aimed to retrospectively examine critical patients admitted to the intensive care unit (ICU) due to COVID-19 from the first onset of cases until September 01, 2020 and to examine the factors affecting mortality. The necessary permits for the study were obtained from the Scientific Research Platform of the T.R. Ministry of Health and the Ethics Committee of the Gazi Yasargil educational and Research Hospital in Diyarbakır. (No: 550, 11.09.2020) Patients diagnosed with COVID-19 on the specified dates, followed in the ICU, older than 18 years, identified as critical/serious according to the World Health Organization and provisional guidelines of the Scientific Board of the T.R. Ministry of Health will be included in the study.
ICU patients without COVID-19; COVID-19 patients under 18 years of age; COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography will be excluded from the study.
Read more
Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Kidney Disease: Improving Global Outcomes (KDIGO) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, Partial oxygen pressure-PO2, Partial pressure of carbon dioxide-PCO2, bicarbonate-HCO3, lactate), coagulation parameters (prothrombin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , urea, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
Patients will be divided into two groups according to their clinical results as those without mortality during ICU follow-up (Group S) and those with mortality (Group NS). The clinical characteristics of both groups, APACHE II, SOFA, KDIGO scores and laboratory results at the first admission to the ICU will be compared. With the diagnosis of COVID-19, factors affecting mortality in critical patients in the ICU will be tried to be determined.
- Conditions
- Covid19 and Mortality
- Being tested
- clinical features and laboratory values
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
clinical features and laboratory valuesDiagnostic test
Patients' age, gender, comorbidity, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
| Study group | Role | What they receive |
|---|---|---|
| Grup S (Survivors) | Survivors in ICU follow-up Receives: Diagnostic Test: clinical features and laboratory values | |
| Grup NS (Nonsurvivors) | Patients who died in ICU follow-up Receives: Diagnostic Test: clinical features and laboratory values |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acute Physiology and Chronic Health Evaluation II Score
The score can help in the assessment of patients to determine the level \& degree of diagnostic \& therapeutic intervention.
Interpretation of APACHE II: minimum 0 and maximum 71; increasing score is associated with an increasing risk of hospital death.
Measured: APACHE II score on the first admission of ICU
Sequential Organ Failure Assessment Score
The Sequential Organ Failure Assessment (SOFA) score is a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category. The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). Score ranges from 0 (best) to 24 (worst) points.
Measured: SOFA score on the first admission of ICU
Kidney Disease: Improving Global Outcomes Scores
It is a system used to determine the severity of kidney failure. It is a classification consisting of four stages: 0-1-2-3. It indicates that the level of failure worsens as the stage increases.
Measured: When the patients were admitted to ICU for the first time.
White Blood Cell
White blood cell count was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission
Neutrophil
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Lymphocyte
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Neutrophil Lymphocyte Ratio
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: the first admission to ICU
Comorbidities
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Diabetes
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Hypertension
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Chronic Obstructive Pulmonary Disease
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Chronic Kidney Disease
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Cardiovascular Disease
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Measured: When the patients were admitted to ICU for the first time
Hemoglobin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Hematocrit
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Platelet
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Prothrombin Time
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
D-dimer
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Blood Gas Analysis-pH
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Partial Oxygen Pressure
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Partial Pressure of Carbon Dioxide
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Bicarbonate
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Lactate
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Lactate Dehydrogenase
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Creatine Kinase
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
C-reactive Protein
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Blood Urea Nitrogen
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Creatinine
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Alanine Aminotransferase
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Aspartate Aminotransferase
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Total Bilirubin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Direct Bilirubin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Indirect Bilirubin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Procalcitonin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Ferritin
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Measured: At ICU admission (first laboratory measurement after ICU admission)
Secondary outcomes (1)
Length of Stay in the Intensive Care Unit
ICU length of stay was measured as the total number of days from ICU admission to ICU discharge or death, based on information recorded in medical records.
Measured: Three months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2020
- Study start22 Mar 2020
- Primary completion1 Sep 2020
- Study completion8 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Covid19 and MortalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 445 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Osman Uzundere, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04659876
- Sponsor's protocol ID
- September 11, 2020: 550
- Status last verified
- Dec 2025
- First submitted
- 8 Dec 2020
- Last updated
- 12 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, Moradmand-Badie B, Seyed Alinaghi SA, Jahanfar S. Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr Med. 2020 Dec;40:101226. doi: 10.1016/j.eujim.2020.101226. Epub 2020 Oct 17.
PubMed 33101547Luo M, Cao S, Wei L, Zhao X, Gao F, Li S, Meng L, Wang Y. Intubation, mortality, and risk factors in critically ill Covid-19 patients: A pilot study. J Clin Anesth. 2020 Dec;67:110039. doi: 10.1016/j.jclinane.2020.110039. Epub 2020 Sep 7. No abstract available.
PubMed 32920347Linli Z, Chen Y, Tian G, Guo S, Fei Y. Identifying and quantifying robust risk factors for mortality in critically ill patients with COVID-19 using quantile regression. Am J Emerg Med. 2021 Jul;45:345-351. doi: 10.1016/j.ajem.2020.08.090. Epub 2020 Sep 3.
PubMed 33046291
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics and Laboratory Values Affecting Mortality in Critical Coronavirus Disease 2019 Patients Followed in the Intensive Care Unit
- ClinicalTrials.gov ID
- NCT04659876
- Acronym / sponsor ID
- September 11, 2020: 550
- Conditions
- Covid19 and Mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 445 participants (actual)
- Lead sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research HospitalUniversity, hospital or other
- Study start
- 22 Mar 2020 (actual)
- Primary completion
- 1 Sep 2020 (actual)
- Study completion
- 8 Dec 2020 (actual)
- First posted
- 9 Dec 2020 (actual)
- Results
- Posted 12 Jan 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak. The first cases in this region were seen on March 22, 2020. In this study, it is aimed to retrospectively examine critical patients admitted to the intensive care unit (ICU) due to COVID-19 from the first onset of cases until September 01, 2020 and to examine the factors affecting mortality. The necessary permits for the study were obtained from the Scientific Research Platform of the T.R. Ministry of Health and the Ethics Committee of the Gazi Yasargil educational and Research Hospital in Diyarbakır. (No: 550, 11.09.2020) Patients diagnosed with COVID-19 on the specified dates, followed in the ICU, older than 18 years, identified as critical/serious according to the World Health Organization and provisional guidelines of the Scientific Board of the T.R. Ministry of Health will be included in the study.
ICU patients without COVID-19; COVID-19 patients under 18 years of age; COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography will be excluded from the study.
Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Kidney Disease: Improving Global Outcomes (KDIGO) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, Partial oxygen pressure-PO2, Partial pressure of carbon dioxide-PCO2, bicarbonate-HCO3, lactate), coagulation parameters (prothrombin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , urea, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
Patients will be divided into two groups according to their clinical results as those without mortality during ICU follow-up (Group S) and those with mortality (Group NS). The clinical characteristics of both groups, APACHE II, SOFA, KDIGO scores and laboratory results at the first admission to the ICU will be compared. With the diagnosis of COVID-19, factors affecting mortality in critical patients in the ICU will be tried to be determined.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Grup S (Survivors) | – | Diagnostic Test: clinical features and laboratory valuesSurvivors in ICU follow-up |
| Grup NS (Nonsurvivors) | – | Diagnostic Test: clinical features and laboratory valuesPatients who died in ICU follow-up |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Critical patients over the age of 18 who were admitted to the ICU
Key inclusion criteria (1 listed)
- During the period between 22.03.2020 and 01.09.2020, critical patients over the age of 18 who were admitted to the ICU of Diyarbakır Gazi Yasargil Educational and Research Hospital due to COVID-19 will be included in the study.
Key exclusion criteria (3 listed)
- ICU patients without COVID-19
- COVID-19 patients under 18 years of age
- COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| clinical features and laboratory valuesPatients' age, gender, comorbidity, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. | Diagnostic test | Grup NS (Nonsurvivors), Grup S (Survivors) |
Primary outcome
Acute Physiology and Chronic Health Evaluation II Score
Time frame: APACHE II score on the first admission of ICU
The score can help in the assessment of patients to determine the level \& degree of diagnostic \& therapeutic intervention. Interpretation of APACHE II: minimum 0 and maximum 71; increasing score is associated with an increasing risk of hospital death.
Sequential Organ Failure Assessment Score
Time frame: SOFA score on the first admission of ICU
The Sequential Organ Failure Assessment (SOFA) score is a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category. The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). Score ranges from 0 (best) to 24 (worst) points.
Kidney Disease: Improving Global Outcomes Scores
Time frame: When the patients were admitted to ICU for the first time.
It is a system used to determine the severity of kidney failure. It is a classification consisting of four stages: 0-1-2-3. It indicates that the level of failure worsens as the stage increases.
White Blood Cell
Time frame: At ICU admission
White blood cell count was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Neutrophil
Time frame: When the patients were admitted to ICU for the first time
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Lymphocyte
Time frame: When the patients were admitted to ICU for the first time
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Neutrophil Lymphocyte Ratio
Time frame: the first admission to ICU
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Comorbidities
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Diabetes
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Hypertension
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Chronic Obstructive Pulmonary Disease
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Chronic Kidney Disease
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Cardiovascular Disease
Time frame: When the patients were admitted to ICU for the first time
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Hemoglobin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Hematocrit
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Platelet
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Prothrombin Time
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
D-dimer
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Blood Gas Analysis-pH
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Partial Oxygen Pressure
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Partial Pressure of Carbon Dioxide
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Bicarbonate
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Lactate
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Lactate Dehydrogenase
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Creatine Kinase
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
C-reactive Protein
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Blood Urea Nitrogen
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Creatinine
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Alanine Aminotransferase
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Aspartate Aminotransferase
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Total Bilirubin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Direct Bilirubin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Indirect Bilirubin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Procalcitonin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Ferritin
Time frame: At ICU admission (first laboratory measurement after ICU admission)
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
1 secondary outcome
Length of Stay in the Intensive Care Unit
Time frame: Three months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 33101547Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, Moradmand-Badie B, Seyed Alinaghi SA, Jahanfar S. Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr Med. 2020 Dec;40:101226. doi: 10.1016/j.eujim.2020.101226. Epub 2020 Oct 17.
- Background: PubMed 32920347Luo M, Cao S, Wei L, Zhao X, Gao F, Li S, Meng L, Wang Y. Intubation, mortality, and risk factors in critically ill Covid-19 patients: A pilot study. J Clin Anesth. 2020 Dec;67:110039. doi: 10.1016/j.jclinane.2020.110039. Epub 2020 Sep 7. No abstract available.
- Background: PubMed 33046291Linli Z, Chen Y, Tian G, Guo S, Fei Y. Identifying and quantifying robust risk factors for mortality in critically ill patients with COVID-19 using quantile regression. Am J Emerg Med. 2021 Jul;45:345-351. doi: 10.1016/j.ajem.2020.08.090. Epub 2020 Sep 3.
- Individual participant dataSharing planned: Undecided
Related trials for Covid19 and Mortality
Active, not recruitingPhase 3
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
Critical Illness, Vitamin D Deficiency
Active, not recruitingObservational study
RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults
Respiratory Syncytial Virus Infections, Immunocompromised Host
RecruitingObservational study
COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor
Coronavirus Infections
Active, not recruitingPhase 2
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and Mortality, run by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acute Physiology and Chronic Health Evaluation II Score (time frame: APACHE II score on the first admission of ICU). The study lists 35 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04659876, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.